ProKidney Corp. (PROK)

NCM – Цена в реальном времени. Валюта: USD

1.83

+0.13 (7.65%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.81

-0.02 (-1.09%)

До открытия: Jun 29, 2026, 4:01 AM EDT

02.06.2026

ProKidney Appoints Kenneth Locke as Chief Technical Officer

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel

15.05.2026

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

15.05.2026

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first quarter ended March 31, 2026, and provided business highlights.

25.03.2026

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer.

31.01.2026

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.

14.01.2026

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

06.01.2026

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

Видео

No Data

There is no data to display

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

10.11.2025

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and provided regulatory and clinical updates.

ProKidney Corp. (PROK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ProKidney Corp. (PROK)

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Search stocks

ProKidney Corp. (PROK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ProKidney Corp. (PROK)

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates